The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV
批准号:
10683771
负责人:
Kaku So-Armah
金额:
$45.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-10 至 2026-08-31
关键词:
AddressAftercareAlcohol abuseAlcohol consumptionAlcoholsAnatomyBehavioralBiological MarkersBiometryBronchiectasisCOVID-19CalendarCarbon MonoxideCause of DeathCollaborationsDataDiagnosisDiffusionDiseaseDisease OutcomeDisease ProgressionEffectiveness of InterventionsEpidemiologyEthanol toxicityFoundationsFutureGoalsHIVHIV/AIDSHIV/TBHealthHealth PersonnelHeavy DrinkingHigh PrevalenceImmune System DiseasesImmunologicsImmunologyInfectious AgentInternationalInterventionInterviewKnowledgeLinkLungLung diseasesLung infectionsMalnutritionMeasuresMethodsObservational StudyOutcomeOutcome AssessmentPerceptionPersonsPhysiologicalPhysiologyPneumoniaPredispositionProductivityPulmonary Function Test/Forced Expiratory Volume 1Pulmonary TuberculosisPulmonary function testsPulmonologyReadinessResearchRespiratory Signs and SymptomsRiskRisk FactorsRoleScanningSeverity of illnessSmokingTestingTimeToxic effectTranslatingTuberculosisTuberculosis diagnosisUgandaVital capacityWalkingWomanWorkX-Ray Computed Tomographyactive methodalcohol effectalcohol interventionalcohol researchalcohol use disorderbehavioral pharmacologyco-infectionexercise capacityhazardous drinkingimprovedinterestlung injurymenmodifiable riskphosphatidylethanolprimary outcomesecondary outcomesmoking interventionsmoking prevalencesubstance usetimelinetreatment adherencetuberculosis treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Modified Project Summary/Abstract Section
Tuberculosis (TB) is the leading cause of death from a single infectious agent and the leading cause of death in people with HIV (PWH). An estimated 8.5 million people with TB are cured every year but many do not return to full health. Up to half of those completing treatment for pulmonary TB have post-TB lung disease, a disabling under-diagnosed group of lung deficits. Lung deficits at TB treatment completion are the strongest predictors of post-TB lung disease severity up to a year later. Alcohol and HIV are associated with lung immune dysfunction and alcohol use is associated with delayed TB diagnosis, increasing the risk of lung injury during active TB disease. However, it is not known whether alcohol use is associated with post-TB lung disease in PWH. We hypothesize that hazardous drinking increases susceptibility to and worsens post-TB lung disease in PWH. Our objective is to investigate hazardous drinking (Alcohol Use Disorders Identification Test [AUDIT] ≥8) as a modifiable risk factor for post-TB lung disease in PWH. To achieve this, we propose an 18- month observational study of 200 PWH completing pulmonary TB treatment in Mbarara, Uganda. We will evaluate the following post-TB lung disease outcomes: functional exercise capacity (primary outcome assessed by 6-minute walk distance), lung physiology (pulmonary function tests), anatomy (CT scan), and lung infections. The primary exposure is past-year hazardous drinking. Secondary alcohol measures will include 30- day Timeline Followback (calendar-based method of alcohol use recall) and phosphatidylethanol (PEth; a biomarker of recent alcohol use). Our expertise spans alcohol use, HIV, TB, pulmonology, epidemiology, and biostatistics. Our primary aim (Aim 1a) is to determine the relationship between past-year hazardous drinking and post-TB lung disease. In Aim 1b we assess the association of past-month heavy drinking and post-TB lung disease progression over time. In Aim 1c we explore whether smoking modifies the association of past- month heavy drinking and post-TB lung disease progression over time. Heavy drinking in Aims 1b and 1c is defined by Timeline Followback as ≥7 drinks/week (women) or ≥14 drinks/week (men) or PEth>200 ng/mL. In Aim 2, we will qualitatively evaluate factors that can improve tailoring of pharmaco-behavioral alcohol and smoking interventions in PWH receiving TB treatment. We will conduct in-depth interviews with 24 PWH during or after TB treatment and 12 TB healthcare providers. IMPACT: We will determine the association of alcohol use and post-TB lung disease in PWH. Our quantitative and qualitative data will lay the foundation for future work to tailor alcohol and smoking interventions to improve long-term health in HIV/TB co-infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)
-
批准号:10304050
-
项目类别:
-
资助金额:$41.84万
-
财政年份:2021
-
负责人:Kaku So-Armah
-
依托单位:
The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV
-
批准号:10303987
-
项目类别:
-
资助金额:$46.0万
-
财政年份:2021
-
负责人:Kaku So-Armah
-
依托单位:
Microbiome, metabolites, and alcohol in HIV to reduce CVD Cohort (META HIV CVD Cohort)
-
批准号:10685515
-
项目类别:
-
资助金额:$37.76万
-
财政年份:2021
-
负责人:Kaku So-Armah
-
依托单位:
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury
-
批准号:9982396
-
项目类别:
-
资助金额:$12.96万
-
财政年份:2016
-
负责人:Kaku So-Armah
-
依托单位:
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury
-
批准号:9750787
-
项目类别:
-
资助金额:$12.66万
-
财政年份:2016
-
负责人:Kaku So-Armah
-
依托单位:
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver Injury
-
批准号:9183689
-
项目类别:
-
资助金额:$11.88万
-
财政年份:2016
-
负责人:Kaku So-Armah
-
依托单位:
海外基金